I. Trouilloud

发表

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

C. Tournigand, T. Mazard, D. Vernerey, 2021, Molecular oncology.

Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study.

R. Coriat, S. Doat, B. Landi, 2020, Clinics and research in hepatology and gastroenterology.

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

J. Taïeb, D. Vernerey, F. Bonnetain, 2016, Journal of the National Cancer Institute.

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".

O. Bouché, D. Vernerey, J. Taieb, 2022, Clinical colorectal cancer.

Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study.

J. Taïeb, D. Vernerey, J. Pagès, 2015, European journal of cancer.

Chemosensitivity in ovarian metastases from gastric cancer: a case series.

P. Rougier, J. Taieb, A. Berger, 2013, Clinics and research in hepatology and gastroenterology.

Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.

M. Housset, P. Rougier, J. Belghiti, 2011, World journal of gastroenterology.

Effectiveness of combined endoscopic ultrasound-guided fine-needle aspiration biopsy and stenting in patients with suspected pancreatic cancer

F. Prat, B. Terris, S. Chaussade, 2012, European journal of gastroenterology & hepatology.

Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.

M. Svrcek, T. André, R. Cohen, 2019, Bulletin du cancer.

Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.

J. Vaillant, A. Sauvanet, J. Taieb, 2019, Clinics and research in hepatology and gastroenterology.

FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.

F. Fein, F. Bonnetain, J. Taieb, 2012 .

Outcomes of surgical management for borderline (BR)/locally advanced (LA) pancreatic adenocarcinoma (PAC) after neoadjuvant FOLFIRINOX chemotherapy: Results of an AGEO/French multicenter study.

J. Vaillant, J. Blanc, R. Coriat, 2014 .

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3‐year single‐centre experience

L. Peyrin-Biroulet, A. Oussalah, M. Bensenane, 2009, Alimentary pharmacology & therapeutics.

Long‐term outcome of non‐fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab

L. Siproudhis, L. Peyrin-Biroulet, G. Bouguen, 2009, Alimentary pharmacology & therapeutics.

Immunotherapy and patients treated for cancer with microsatellite instability.

A. Duval, J. Lefèvre, J. Fléjou, 2017, Bulletin du cancer.

Nouvelles classifications moléculaires du cancer colorectal, du cancer du pancréas et du cancer de l’estomac : vers un traitement à la carte ?

C. Dreyer, T. André, P. Afchain, 2016 .

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

F. Carbonnel, J. Blanc, J. Taieb, 2014, Annals of Surgical Oncology.

Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

A. Lièvre, B. Rousseau, C. Vitellius, 2019, The oncologist.

Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma.

D. Vernerey, P. Hammel, S. Doat, 2020, Clinics and research in hepatology and gastroenterology.

Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.

J. Taieb, D. Tougeron, S. Pernot, 2020, Clinics and research in hepatology and gastroenterology.

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

D. Pezet, J. Taieb, D. Tougeron, 2019, Therapeutic advances in gastroenterology.

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

F. Fein, F. Bonnetain, J. Taieb, 2015, PloS one.

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

J. Taieb, T. Aparicio, M. Gauthier, 2014, BMC Cancer.

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

J. Taïeb, F. Fein, F. Bonnetain, 2014, European journal of cancer.

Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort

P. Innominato, O. Hentic, J. Blanc, 2015, Annals of Surgical Oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues

A. Lièvre, W. Cacheux, J. Taieb, 2015, Cancer.

Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study

A. Lièvre, P. Hammel, J. Taieb, 2022, International journal of cancer.

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.

J. Taieb, B. Landi, J. Bachet, 2011, Clinics and research in hepatology and gastroenterology.

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma

C. Tournigand, C. Lepage, A. Bertaut, 2023, Journal of gastrointestinal oncology.

Digital tool to identify and monitor regorafenib-associated hand-foot skin reactions: A proof-of-concept study protocol.

V. Bourgeois, M. Palma, R. Coriat, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study.

D. Vernerey, F. Bonnetain, J. Taieb, 2014 .

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3‐year single‐centre experience

L. Peyrin-Biroulet, A. Oussalah, M. Bensenane, 2009, Alimentary pharmacology & therapeutics.

Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

O. Bouché, L. Mineur, J. Metges, 2022, Journal of Clinical Oncology.